IFN beta-1a - versus standard of care - for COVID-19 severe or critically pdf   xlsx method abbreviations

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA

efficacy endpoints 00

death D28 0.30 [0.11, 0.83]< 10%1 study (1/-)99.0 %NAnot evaluable crucial-
deaths 0.38 [0.16, 0.87]< 10%1 study (1/-)98.8 %NAnot evaluable crucial-
deaths (time to event analysis only) 0.38 [0.16, 0.87]< 10%1 study (1/-)98.8 %NAnot evaluable crucial-
clinical improvement 1.10 [0.64, 1.88]> 10%1 study (1/-)63.6 %NAnot evaluable important-
clinical improvement (time to event analysis only) 1.10 [0.64, 1.88]> 10%1 study (1/-)63.6 %NAnot evaluable important-
hospital discharge 1.96 [0.76, 5.03]> 10%1 study (1/-)91.9 %NAnot evaluable important-
mechanical ventilation 0.72 [0.29, 1.76]< 10%1 study (1/-)76.5 %NAnot evaluable important-
off oxygenation 8.57 [1.43, 51.36]> 10%1 study (1/-)99.0 %NAnot evaluable non important-

safety endpoints 00

superinfection 2.41 [0.75, 7.73]< 10%1 study (1/-)6.9 %NAnot evaluable important-

LoD: level of statistical demonstration: Statistically conclusive: statistically significant with a strict control of overall risk of type 1 error (statistically demonstrated), does not take into account the risk of bias; suggested: nominally statistically significant but without a strict control of overall risk of type 1 error; inconclusive: not nominally statistically significant; safety concerns;
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.